<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796766</url>
  </required_header>
  <id_info>
    <org_study_id>MiPro-CGRP</org_study_id>
    <nct_id>NCT04796766</nct_id>
  </id_info>
  <brief_title>Human Electrophysiological Model to Quantify the CGRP-related Axon Reflex of Trigeminal Afferents</brief_title>
  <acronym>MiPro-CGRP</acronym>
  <official_title>Establishment of a Human Electrophysiological Model to Quantify the Calcitonin Gene-related Peptide (CGRP)-Related Axon Reflex of Trigeminal Afferents and Its Evaluation as a Clinical Tool to Assess and Predict Treatment Effects of Migraine Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed project aims at establishing Calcitonin gene-related peptide (CGRP)-Related Axon&#xD;
      Reflex of Trigeminal Afferents as a neurophysiological biomarker for migraine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed project aims at establishing a neurophysiological biomarker for migraine.&#xD;
      Migraine is one of the world's most disabling diseases and its prophylactic treatment is time&#xD;
      and cost-consuming. Since each patient responds differently and unpredictably to preventive&#xD;
      medication, physicians are forced to try prophylactic drugs one by one. Recently, a new group&#xD;
      of therapeutic agents targeting the neuropeptide Calcitonin gene-related peptide (CGRP) has&#xD;
      been launched for migraine treatment. CGRP is stored in trigeminal afferents and released to&#xD;
      meningeal blood vessels during acute migraine attacks leading to a vasodilating response. In&#xD;
      an experimental setting, the release of CGRP from afferent nerve fibers in the skin can be&#xD;
      induced by transdermal electrical stimulation. The subsequently evoked skin erythema, called&#xD;
      'flare reaction', can be quantified by laser Doppler imaging techniques. Never before,&#xD;
      research studies used this experimental model in either trigeminally innervated skin or&#xD;
      migraine patients. I therefore propose to establish this model to 1) test the specificity of&#xD;
      an evoked 'flare response' in the trigeminal territory for the pathophysiology of migraine,&#xD;
      2) investigate the effect of CGRP-targeting anti-migraine drugs on this outcome parameter and&#xD;
      3) evaluate the impact of this model to predict the treatment response to drugs interfering&#xD;
      with the CGRP-pathway. This study is a highly innovative approach towards tailored migraine&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of axonal flare reaction</measure>
    <time_frame>Day 1</time_frame>
    <description>Axon reflex erythema of stimulated C-nociceptors measured in Flux (luminous flux) values 0 - 100.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFS / LFS in healthy volunteers at two different points in time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Migraine patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFS / LFS in migraine patients at a single point in time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Botulinum toxin or CGRP-targeted therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFS / LFS before and under treatment with Botulinum toxin or CGRP-targeted therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>High frequency stimulation (HFS)</intervention_name>
    <description>Electrical stimuli via circular electrode array. The electrode array serves as cathode placed above the eyebrow. A surface electrode (anode) will be placed on the temple. Electrical stimuli will be applied via a constant current stimulator. The stimulus intensity for the electrophysiological protocol is adjusted to the 10-fold of the detection threshold. A number of 5 electrical pulses (2 ms, 100 Hertz (Hz)), 10 second intervals.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Migraine patients</arm_group_label>
    <arm_group_label>Patients with Botulinum toxin or CGRP-targeted therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Low-frequency sinusoidal transcutaneous stimulation (sLFS)</intervention_name>
    <description>Stimulation of C-nociceptors with constant current stimulator. Electrodes (placed on the proband's forehead. Stimulation by sine wave pulses of 250 ms duration (4 Hz), intensities inducing a pain intensity of 50/100 on a visual analogue scale from 0-100.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Migraine patients</arm_group_label>
    <arm_group_label>Patients with Botulinum toxin or CGRP-targeted therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy volunteers (Study Arm 1 and 2):&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  good German language skills&#xD;
&#xD;
          -  no history of head trauma&#xD;
&#xD;
          -  no history of neurologic disease&#xD;
&#xD;
          -  no primary headache disorder (e.g. migraine, episodic or chronic tension type&#xD;
             headache, cluster headache)&#xD;
&#xD;
          -  no regular drug intake (except for oral contraceptives)&#xD;
&#xD;
        Migraine patients need to match the following criteria (Study Arm 2 and 3):&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  good German language skills&#xD;
&#xD;
          -  fulfilling the diagnostic criteria for either episodic or chronic migraine with or&#xD;
             without aura according to the international classification of headache disorders&#xD;
             (ICHD) 3rd edition&#xD;
&#xD;
          -  history of migraine &gt; 1 year&#xD;
&#xD;
          -  keeping a headache diary for a minimum of 3 months prior to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy volunteers and migraine patients under the following conditions will be excluded:&#xD;
&#xD;
          -  Chronic pain syndromes (e.g. low back pain, osteoarthritis, painful neuropathy,&#xD;
             rheumatoid arthritis)&#xD;
&#xD;
          -  Acute pain (e.g. pain due to acute skin injury, menstrual pain, acute toothache). In&#xD;
             this case, a measurement can only be performed after complete remission of pain and at&#xD;
             least 48 hours after intake of acute pain medication (e.g. triptans, non-steroidal&#xD;
             anti-inflammatory drug (NSAID)).&#xD;
&#xD;
          -  history of treatment with agents targeting the CGRP pathway (e.g. erenumab) &lt; 3 months&#xD;
             before the study&#xD;
&#xD;
          -  history of treatment with Botulinum toxin &lt; 9 months before the study&#xD;
&#xD;
          -  Diseases of the skin involving the skin at face and forehead&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Subjects lacking capacity for consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sigrid Schuh-Hofer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tübingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sigrid Schuh-Hofer, Prof. Dr.</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>80416</phone_ext>
    <email>sigrid.schuh-hofer@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victoria Ruschil, Dr.</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>86123</phone_ext>
    <email>victoria.ruschil@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Ruschil, Dr.</last_name>
      <phone>+49 7071 29</phone>
      <phone_ext>86123</phone_ext>
      <email>victoria.ruschil@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Sigrid Schuh-Hofer, Prof. Dr.</last_name>
      <phone>+49 7071 29</phone>
      <phone_ext>80416</phone_ext>
      <email>sigrid.schuh-hofer@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Calcitonin gene-related peptide (CGRP)</keyword>
  <keyword>Evoked flare response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

